BEVERLY, Mass.--(BUSINESS WIRE)--Cellanyx Diagnostics announced today that it will present at the ASCO Genitourinary Cancers Symposium, in Orlando, Florida, their first clinical data in prostate cancer with a novel live tumor cell phenotypic diagnostic test. Data will be presented at a poster session which demonstrate the test’s potential to stratify the risk of tumor advancement and metastasis in patients diagnosed with low and intermediate Gleason scores in prostate cancer. The test is designed to provide a new tool to aid clinical decision making for patient care.
The poster (No. 211) is entitled, Novel Live Tumor Cell Diagnostic Test Utilizing Biophysical and Molecular Biomarkers to Assess Local, Advanced, and Metastatic Prostate Cancer,” and will be presented Feb. 27 at 12:15PM-1:45PM ET and 6:00PM-7:00PM ET.
Help employers find you! Check out all the jobs and post your resume.
The poster (No. 211) is entitled, Novel Live Tumor Cell Diagnostic Test Utilizing Biophysical and Molecular Biomarkers to Assess Local, Advanced, and Metastatic Prostate Cancer,” and will be presented Feb. 27 at 12:15PM-1:45PM ET and 6:00PM-7:00PM ET.
Help employers find you! Check out all the jobs and post your resume.
